本指南由时任ESVS大会副主席Marianne De Maeseneer女士，全权授权予纪永威教授(中国台湾)将欧洲慢性静脉疾病诊疗指南，为海峡两岸及港澳地区以及其他使用中文服务于患者的医生同业提供无偿服务。纪教授邀请陈忠教授、符伟国教授、郭伟教授三位教授共同编译，连续连载，为广大医疗专业人士提供重要的资源，帮助他们根据最新的临床证据为CVD患者制定个性化的治疗方案。   

☆4.证据和建议标准☆

    欧洲心脏病学会（European Society of Cardiology，ESC）体系用于对证据和建议进行分级。A、B或C反映了当前证据的级别(表1)，每个建议的强度分为Ⅰ、Ⅱa、Ⅱb或Ⅲ级(表2)。

    为了制定建议，我们考虑了现有证据的优势和局限、益处和危害以及对临床实践的适用性。在正文中讨论了研究方法局限性的细节、主要和次要结果的适当性以及研究结果的一致性。

☆5.证据表☆

    委员会成员在证据表（Tables of Evidence,ToEs）中提供了选定文章的摘要，用于支持不同建议的证据。这些表格可以作为补充材料在网上获得。

☆  4. Evidence and Recommendations criteria. ☆ 

        The European Society of Cardiology (ESC) system was used for grading evidence and recommendations. A, B, or C reflects the level of current evidence (Table1) and the strength of each recommendation was then determined to be class I, IIa, IIb, or III (Table 2).

       To formulate recommendations, the strengths and limita tions of the available evidence were considered, as well as benefit versus harm and applicability to clinical practice context. Details of study methodology limitations, appropri ateness of primary and secondary outcomes, and consistency of results across studies were discussed in the main text.

☆ 5. Tables of Evidence. ☆

       The members of the GWC provided summaries of the selected articles, used to support the evidence for the different recommendations, in Tables of Evidence (ToEs). These ToEs are available online, as Supplementary Material.